Target analysis of the experimental measles therapeutic AS-136A

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3860-3870

  Yoon, Jeong Joong ^a   Krumm, Stefanie A ^a   Ndungu, J Maina ^b   Hoffman, Vanessa ^a   Bankamp, Bettina ^c   Rota, Paul A ^c   Sun, Aiming ^c   Snyder, James P ^c   Plemper, Richard K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AS 136A; DIHYDROLIPOAMIDE DEHYDROGENASE; MEASLES VACCINE; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; MEASLES; MEASLES VIRUS; NONHUMAN; PARAMYXOVIRUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; VERO CELL; VIROGENESIS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; HUMANS; MEASLES; MEASLES VIRUS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL;

EID: 70349100411     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00503-09     Document Type: Article

References (58)

1. Bankamp, B., S. P. Kearney, X. Liu, W. J. Bellini, and P. A. Rota. 2002. Activity of polymerase proteins of vaccine and wild-type measles virus strains in a minigenome replication assay. J. Virol. 76:7073-7081. (Pubitemid 41246221)
2. Bose, S., and A. K. Banerjee. 2004. Beta-catenin associates with human parainfluenza virus type 3 ribonucleoprotein complex and activates transcription of viral genome RNA in vitro. Gene Expr. 11:241-249. (Pubitemid 38735924)
3. Bowman, M. C., S. Smallwood, and S. A. Moyer. 1999. Dissection of individual functions of the Sendai virus phosphoprotein in transcription. J. Virol. 73:6474-6483.
4. Buchholz, U. J., S. Finke, and K. K. Conzelmann. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J. Virol. 73:251-259.
5. Cattaneo, R., G. Rebmann, K. Baczko, V. ter Meulen, and M. A. Billeter. 1987. Altered ratios of measles virus transcripts in diseased human brains. Virology 160:523-526.
6. Centers for Disease Control and Prevention. 2008. Update: measles - United States, January-July 2008. MMWR Morb. Mortal. Wkly. Rep. 57: 893-896.
7. Centers for Disease Control and Prevention. 2008. Progress in global measles control and mortality reduction, 2000-2007. MMWR Morb. Mortal. Wkly. Rep. 57:1303-1306.
8. Cevik, B., D. E. Holmes, E. Vrotsos, J. A. Feller, S. Smallwood, and S. A. Moyer. 2004. The phosphoprotein (P) and L binding sites reside in the N-terminus of the L subunit of the measles virus RNA polymerase. Virology 327:297-306. (Pubitemid 39209334)
9. Cevik, B., S. Smallwood, and S. A. Moyer. 2007. Two N-terminal regions of the Sendai virus L RNA polymerase protein participate in oligomerization. Virology 363:189-197. (Pubitemid 46678171)
10. Chattopadhyay, A., T. Raha, and M. S. Shaila. 2004. Effect of single amino acid mutations in the conserved GDNQ motif of L protein of rinderpest virus on RNA synthesis in vitro and in vivo. Virus Res. 99:139-145. (Pubitemid 38121663)
11. Chattopadhyay, A., and M. S. Shaila. 2004. Rinderpest virus RNA polymerase subunits: mapping of mutual interacting domains on the large protein L and phosphoprotein p. Virus Genes 28:169-178. (Pubitemid 38393424)
12. Curran, J., T. Pelet, and D. Kolakofsky. 1994. An acidic activation-like domain of the Sendai virus P protein is required for RNA synthesis and encapsidation. Virology 202:875-884. (Pubitemid 24254901)
13. De Clercq, E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5:1015-1025.
14. De Clercq, E. 2004. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem. Biodivers. 1:44-64.
15. De Clercq, E. 1998. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antivir. Res. 38:153-179.
16. Doyle, J., A. Prussia, L. K. White, A. Sun, D. C. Liotta, J. P. Snyder, R. W. Compans, and R. K. Plemper. 2006. Two domains that control prefusion stability and transport competence of the measles virus fusion protein. J. Virol. 80:1524-1536. (Pubitemid 43134108)
17. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
18. European Centre for Disease Prevention and Control. 3 July 2008, posting date. Measles once again endemic in the United Kingdom. http://www .eurosurveillance.org/ViewArticle.aspx?ArticleId=18919.
19. Firsching, R., C. J. Buchholz, U. Schneider, R. Cattaneo, V. ter Meulen, and J. Schneider-Schaulies. 1999. Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J. Virol. 73:5265-5273.
20. Griffin, D. E. 2007. Measles virus, p. 1551-1585. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed., vol.1. Lippincott Williams & Wilkins, Philadelphia, PA.
21. Hayden, F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1):S3-S13.
22. Hilleman, M. R. 2001. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 20:651-665.
23. Holmes, D. E., and S. A. Moyer. 2002. The phosphoprotein (P) binding site resides in the N terminus of the L polymerase subunit of Sendai virus. J. Virol. 76:3078-3083.
24. Horikami, S. M., J. Curran, D. Kolakofsky, and S. A. Moyer. 1992. Complexes of Sendai virus NP-P and P-L proteins are required for defective interfering particle genome replication in vitro. J. Virol. 66:4901-4908.
25. Katz, S. L. 2006. Polio - new challenges in 2006. J. Clin. Virol. 36:163-165.
26. Kremer, J. R., and C. P. Muller. 2009. Measles in Europe - there is room for improvement. Lancet 373:356-358.
27. Lamb, R. A., and G. D. Parks. 2007. Paramyxoviridae: the viruses and their replication, p. 1449-1496. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed., vol.1. Lippincott Williams & Wilkins, Philadelphia, PA.
28. Lee, J. K., A. Prussia, J. P. Snyder, and R. K. Plemper. 2007. Reversible inhibition of the fusion activity of measles virus F protein by an engineered intersubunit disulfide bridge. J. Virol. 81:8821-8826.
29. Liu, X., B. Bankamp, W. Xu, W. J. Bellini, and P. A. Rota. 2006. The genomic termini of wild-type and vaccine strains of measles virus. Virus Res. 122:78-84. (Pubitemid 44740330)
30. Malur, A. G., N. K. Gupta, P. De Bishnu, and A. K. Banerjee. 2002. Analysis of the mutations in the active site of the RNA-dependent RNA polymerase of human parainfluenza virus type 3 (HPIV3). Gene Expr. 10:93-100.
31. Mellors, J. W., G. E. Dutschman, G. J. Im, E. Tramontano, S. R. Winkler, and Y. C. Cheng. 1992. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol. Pharmacol. 41:446-451.
32. Moss, W. J., and D. E. Griffin. 2006. Global measles elimination. Nat. Rev. Microbiol. 4:900-908.
33. Moyer, S. A., S. C. Baker, and S. M. Horikami. 1990. Host cell proteins required for measles virus reproduction. J. Gen. Virol. 71:775-783.
34. Moyer, S. A., S. C. Baker, and J. L. Lessard. 1986. Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc. Natl. Acad. Sci. USA 83:5405-5409.
35. Oberg, B. 2006. Rational design of polymerase inhibitors as antiviral drugs. Antivir. Res. 71:90-95.
36. Ono, N., H. Tatsuo, Y. Hidaka, T. Aoki, H. Minagawa, and Y. Yanagi. 2001. Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor. J. Virol. 75:4399-4401. (Pubitemid 32410152)
37. Orenstein, W. A., M. J. Papania, and M. E. Wharton. 2004. Measles elimination in the United States. J. Infect. Dis. 189(Suppl. 1):S1-S3.
38. Orenstein, W. A., P. M. Strebel, M. Papania, R. W. Sutter, W. J. Bellini, and S. L. Cochi. 2000. Measles eradication: is it in our future? Am. J. Public Health 90:1521-1525.
39. Palese, P., and M. L. Shaw. 2007. Orthomyxoviridae: the viruses and their replication, p. 1647-1690. In D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman, and S. E. Straus (ed.), Fields virology, 5th ed., vol.2. Lippincott Williams & Wilkins, Philadelphia, PA.
40. Parks, G. D. 1994. Mapping of a region of the paramyxovirus L protein required for the formation of a stable complex with the viral phosphoprotein P. J. Virol. 68:4862-4872.
41. Plemper, R. K., J. Doyle, A. Sun, A. Prussia, L. T. Cheng, P. A. Rota, D. C. Liotta, J. P. Snyder, and R. W. Compans. 2005. Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob. Agents Chemother. 49:3755-3761.
42. Plemper, R. K., K. J. Erlandson, A. S. Lakdawala, A. Sun, A. Prussia, J. Boonsombat, E. Aki-Sener, I. Yalcin, I. Yildiz, O. Temiz-Arpaci, B. Tekiner, D. C. Liotta, J. P. Snyder, and R. W. Compans. 2004. A target site for template-based design of measles virus entry inhibitors. Proc. Natl. Acad. Sci. USA 101:5628-5633.
43. Plemper, R. K., A. L. Hammond, D. Gerlier, A. K. Fielding, and R. Cattaneo. 2002. Strength of envelope protein interaction modulates cytopathicity of measles virus. J. Virol. 76:5051-5061.
44. Prussia, A. J., R. K. Plemper, and J. P. Snyder. 2008. Measles virus entry inhibitors: a structural proposal for mechanism of action and the development of resistance. Biochemistry 47:13573-13583.
45. Radecke, F., P. Spielhofer, H. Schneider, K. Kaelin, M. Huber, C. Dotsch, G. Christiansen, and M. A. Billeter. 1995. Rescue of measles viruses from cloned DNA. EMBO J. 14:5773-5784.
46. Richman, D., C. K. Shih, I. Lowy, J. Rose, P. Prodanovich, S. Goff, and J. Griffin. 1991. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88:11241-11245.
47. Rota, P. A., D. A. Featherstone, and W. J. Bellini. 2009. Molecular epidemiology of measles virus. Curr. Top. Microbiol. Immunol. 330:129-150.
48. Ryan, K. W., E. M. Morgan, and A. Portner. 1991. Two noncontiguous regions of Sendai virus P protein combine to form a single nucleocapsid binding domain. Virology 180:126-134.
49. Sidhu, M. S., J. Chan, K. Kaelin, P. Spielhofer, F. Radecke, H. Schneider, M. Masurekar, P. C. Dowling, M. A. Billeter, and S. A. Udem. 1995. Rescue of synthetic measles virus minireplicons: measles genomic termini direct efficient expression and propagation of a reporter gene. Virology 208:800-807.
50. Spearman, C. 1908. The method of right and wrong cases (constant stimuli) without Gauss's formula. Br. J. Psychol. 2:227-242.
51. Statens Serum Institut. 16 July 2008, posting date. Measles surveillance first quarterly report 2008. http://www.euvac.net/graphics/euvac/pdf/2008-first. pdf.
52. Statens Serum Institut. 10 September 2008, posting date. Measles surveillance second quarterly report 2008. http://www.euvac.net/graphics/euvac/ pdf /2008-second.pdf.
53. Sun, A., N. Chandrakumar, J. J. Yoon, R. K. Plemper, and J. P. Snyder. 2007. Non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: synthesis and in vitro evaluation. Bioorg. Med. Chem. Lett. 17:5199-5203.
54. Sun, A., J. J. Yoon, Y. Yin, A. Prussia, Y. Yang, J. Min, R. K. Plemper, and J. P. Snyder. 2008. Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J. Med. Chem. 51:3731-3741.
55. Tan, S. L., G. Ganji, B. Paeper, S. Proll, and M. G. Katze. 2007. Systems biology and the host response to viral infection. Nat. Biotechnol. 25:1383-1389.
56. United Kingdom Health Protection Agency. 28 November 2008, posting date. Health protection report. Confirmed measles cases in England and Wales-an update to the end of October 2008. http://www.hpa.org.uk/hpr /archives/2008/news4808. htm#measles.
57. White, L. K., J. J. Yoon, J. K. Lee, A. Sun, Y. Du, H. Fu, J. P. Snyder, and R. K. Plemper. 2007. Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob. Agents Chemother. 51:2293-2303.
58. World Health Organization. 1998. Expanded programme on immunization (EPI). Wkly. Epidemiol. Rec. 73:265-272.